PAVmed (FRA:1P5) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1P5 PAVmed Inc FRA:1P5
35 GF Score
Price €4.13
GF Value €0.93
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is PAVmed Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:1P5
35GF Score
PAVmed Inc FRA:1P5
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PAVmed (FRA:1P5) Overvalued in 2026?

Based on GuruFocus' analysis, PAVmed stock appears to be overvalued. The current stock price of €4.13 is trading 343.5% above its estimated GF Value™ of €0.93. GuruFocus considers PAVmed to be Significantly Overvalued.

Key valuation signals for FRA:1P5:

  • Interest Received:
  • GF Value™: €0.93 vs. price of €4.13 (343.5% above fair value)
  • GF Score™: 35/100 with 6 warning signs

No single metric tells the full story. See the FRA:1P5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PAVmed Business Description

Other Exchanges PAVM:USA
Address 360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
35GF Score

Get the complete analysis for FRA:1P5

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.13
Price
€0.93
GF Value